Claire Dawson
The Delta variant of COVID-19, which originated in India, was the predominant variant worldwide until November 2021 when Omicron took over. The Delta variant is more infectious than the Wuhan variant and less infectious than the Omicron variant. While hospitals do test for COVID-19, they do not always test for the specific variant. For example, UF Health Jacksonville doctors took it upon themselves to determine what percent of their COVID patients had the Delta variant because the state health department only tests a random sample of COVID-19 tests. In England, 45% of Delta hospital patients only tested positive after admission for a diagnosis unrelated to COVID. While there is no approved test to determine each individual's variant, a national network of state and other labs use genome-sequencing tests to track variants broadly in communities.
| Characteristics | Values |
|---|---|
| Hospitals testing for the Delta variant | UF Health Jacksonville |
| Year | 2021 |
| Month | August |
| Percentage of patients with the Delta variant | 90% |
| Number of tests conducted | 10 |
| State conducting the most tests | Texas |
| Treatment for the Delta variant | Remdesivir, Molnupiravir, Nirmatrelvir, corticosteroids, prophylactic heparin |
| Vaccines with the highest protection rates | mRNA (Pfizer and Moderna) |
| Vaccines with the lowest protection rates | Viral vector vaccines (AstraZeneca and Janssen) |
Explore related products
What You'll Learn
Hospitals take matters into their own hands
As hospitals across the United States witnessed a surge in COVID-19 cases, many were left wondering how many of these cases were the Delta variant. However, most hospitals were unable to answer this question. This uncertainty was due to the state health department's approach of only testing a random sample of COVID-19 tests, rather than those specifically entering hospitals. Consequently, hospitals were not provided with the data they needed to understand the prevalence of the Delta variant among their patients.
UF Health Jacksonville is one such hospital that decided to address this issue by taking matters into their own hands. Through genetic sequencing, doctors and scientists at UF Health Jacksonville sought to identify the percentage of their COVID-19 patients infected with the Delta variant. Dr. Brett Baskovich, director of molecular pathology, played a pivotal role in this endeavour, leveraging his expertise in genetic sequencing to track COVID-19 mutations.
Their efforts revealed that 9 out of 10 patients at UF Health Jacksonville were infected with the Delta variant. While the small sample size of 10 tests limited the scope of their findings, the hospital expressed readiness to conduct more tests under the hospital's direction. By taking the initiative to conduct their own testing, the hospital gained valuable insights that could inform their planning and decision-making processes.
The lack of widespread testing for the Delta variant has been a challenge in tailoring treatments for patients. Without quick and accessible tests, healthcare providers face difficulties in determining whether patients have the Delta or Omicron variant. This gap in testing capabilities has significant implications for patient care, particularly in regions where both variants are prevalent.
While at-home COVID-19 tests are widely available, they are generally less effective in detecting asymptomatic cases. According to a study published in the journal Microbiology Spectrum, Binax COVID tests detected approximately 90% of symptomatic cases but only about 50% of asymptomatic infections. This limitation underscores the importance of repeat testing to reduce the likelihood of false negatives. Overall, the availability and effectiveness of at-home tests vary, and they may not offer a comprehensive solution for identifying the specific COVID-19 variant a person is infected with.
Sterilization Strategies: Keeping Contaminants at Bay
You may want to see also
Explore related products
Genomic sequencing to identify Delta
Genomic sequencing is a powerful tool that has been used to monitor the evolution of SARS-CoV-2 and identify variants, including the Delta variant. This technique has provided valuable insights into the spread and impact of different variants, such as the Delta variant, which was the predominant strain of COVID-19 worldwide until November 2021.
Genomic sequencing allows scientists to identify SARS-CoV-2 and track its mutations over time. It offers a comprehensive view of how the virus is evolving, enabling the development of accurate diagnostics, effective therapeutics, and prophylactic vaccines. The process involves analysing millions of SARS-CoV-2 sequences deposited in genomic sequencing databases, such as GenBank, BV-BRC, and GISAID. These sequences are annotated with dates and geographic locations, allowing for the extraction of nucleotide and amino acid substitutions. By aggregating this data into concise datasets, researchers can assess the spread of variants across space and time.
During the surge of the Delta variant, genomic sequencing played a crucial role in its identification and monitoring. For instance, doctors at UF Health Jacksonville used genomic sequencing to determine the prevalence of the Delta variant among their COVID-19 patients. They found that 9 out of 10 patients at their facility had the Delta variant. This information helped them understand the impact of the variant and plan accordingly.
However, it is important to note that genomic sequencing for variant identification is typically not performed on every viral sample due to the high volume of COVID-19 cases. Instead, it is often used in conjunction with qPCR analysis and targeted sampling strategies to monitor the spread of variants and make informed public health decisions.
In summary, genomic sequencing has been a valuable tool for identifying and tracking the Delta variant of SARS-CoV-2. It provides a comprehensive view of the virus's evolution, enabling researchers and healthcare professionals to better understand its impact and make informed decisions to protect public health.
Benzos and Ambien: What Hospitals Prescribe for Sleep and Anxiety
You may want to see also
Explore related products
No quick test to diagnose Delta
While hospitals are testing for COVID-19, there is no quick test to diagnose the Delta variant. The methods to diagnose the Delta variant are the same as for previous variants, including rapid antigen tests and PCR tests. However, antigen tests in vaccinated people have been found to be less sensitive, producing more false negatives. As a result, a vaccinated person who tests negative on an antigen test cannot be ruled out as uninfected with the Delta variant. On the other hand, a positive test result indicates a high probability of infection.
PCR tests are still effective in detecting the Delta variant. Vaccination has been shown to reduce the infection rate, hospitalisation rate, and mortality rate for the Delta variant. Studies in the United States have revealed that the vast majority of hospitalisations are unvaccinated individuals.
In the absence of a quick test for the Delta variant, doctors face challenges in making treatment decisions. High-risk patients infected with the Delta variant could benefit from specific monoclonal antibody treatments that reduce hospitalisation and death. However, these treatments may not be effective for other variants, such as Omicron, further complicating the treatment landscape.
To identify the prevalence of the Delta variant, some hospitals have taken matters into their own hands. For example, UF Health Jacksonville doctors employed genetic sequencing to determine the percentage of their COVID-19 patients with the Delta variant. They utilised a machine that analysed the genetic sequencing of the current strain compared to the samples being tested. However, the cost and time involved limited the number of tests they could perform.
As of November 2021, the Delta variant was the predominant variant worldwide, but it has since been surpassed by the Omicron variant. The Delta variant originated in India and exhibited changes in the E484K and L452R genes, making the virus more contagious and reducing the response of natural and vaccine antibodies.
Hospitals: Breeding Grounds for Infections and Superbugs
You may want to see also
Explore related products
![The Hospital [DVD]](https://m.media-amazon.com/images/I/61oQ2sBPcmL._AC_UY218_.jpg)
Hospitals grapple with uneven mix of variants
As of January 2022, the Omicron variant was on the rise, but the Delta variant was still prevalent in the Great Plains and parts of the West Coast, including California. This mix of variants has complicated treatments, as there is no quick test to determine which variant a patient has.
In Maryland, where cases were spiking, Omicron accounted for around 58% of them. However, with no approved test to determine each individual variant, health systems have had to rely on regional estimates or their own data to decide on treatments.
Doctors at UF Health Jacksonville in Florida took matters into their own hands to find out how widespread the Delta variant was in their patients, as the state health department only tests a random sample of COVID-19 tests and not those coming into hospitals. Through genetic sequencing, they found that 9 out of 10 patients at UF Health Jax had the Delta variant.
In England, data from Public Health England showed that 43% of patients hospitalised with the Delta variant had likely come to A&E for a diagnosis unrelated to COVID-19 and tested positive later through routine swabbing. This highlights the challenge of managing an uneven mix of variants, as it is difficult to determine whether hospitalisations are primarily due to COVID-19 or incidental findings.
Vaccination has been shown to drastically reduce the probability of severe illness and hospitalisation due to the Delta variant. Studies have found that two doses of mRNA vaccines (such as Pfizer and Moderna) offer 80% protection against severe disease, while one dose provides only 30% protection.
Hospital Hues: Impacting Patient Behavior and Experience
You may want to see also
Delta variant testing at home
The Delta variant of COVID-19 was first identified in India and is 60% more contagious than the original strain. While hospitals and health systems are working to determine the prevalence of the Delta variant among COVID-19 patients, there is currently no approved test to determine each individual case. However, at-home COVID-19 tests should still work against new variants, including the Delta variant.
At-home COVID-19 tests are widely available at drugstores, supermarkets, and online retailers, and they can provide rapid results within 15 minutes. These tests look for antigens, or proteins, from the SARS-CoV-2 virus, which have remained fairly stable even as the virus mutates. Research suggests that antigen tests are generally effective in detecting a variety of COVID-19 variants and are most accurate when the person being tested has respiratory symptoms.
It is important to note that at-home COVID-19 tests may have a higher chance of producing false negatives, especially if used improperly or when the person being tested is asymptomatic. As such, it is recommended to repeat the test 48 hours later to reduce the chance of a false negative. Additionally, it is crucial to choose a test kit that has been approved by the FDA and has a high accuracy rate to ensure reliable results.
Some recommended at-home COVID-19 test kits that detect the Delta variant include the BinaxNOW COVID-19 Antigen Self Test and the On/Go One test. These tests are easy to use, provide fast results, and have been shown to detect multiple COVID-19 variants. Overall, at-home testing provides a safe and comfortable method for individuals to test themselves and their family members without having to visit crowded testing centers.
Face Masks: Still Necessary in Hospitals?
You may want to see also
Frequently asked questions
Hospitals do not usually test for the Delta variant. However, some hospitals, such as UF Health Jacksonville, have taken it upon themselves to test for the variant due to the lack of widespread testing.
Hospitals that do test for the Delta variant use genetic or genome sequencing to identify the variant.
According to testing done by UF Health Jacksonville, 9 out of 10 COVID-19 patients at their hospital had the Delta variant.
Studies suggest that patients infected with the Delta variant have twice the risk of hospitalisation compared to the Alpha variant. The Delta variant has also been found to be more likely to lead to hospitalisation than the Omicron variant.
Vaccines do provide protection against hospitalisation caused by the Delta variant. Studies have shown that unvaccinated individuals make up the majority of hospitalisations due to the Delta variant.
